> ## Content Index > Fetch the complete content index at: https://curo.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # BPC-157: what FDA's 2026 briefing document covers, section by section - URL: https://curo.ghost.io/bpc-157-fda-briefing-document/ - Published: 2026-10-15T20:15:28.000Z - Updated: 2026-10-15T20:15:28.000Z - Author: Romio - Tags: Peptide research BPC-157 has a long paper trail in animal studies and a short one in people. FDA's briefing document for its July 2026 advisory committee, dated May 11, 2026, reviews that record in detail. This post walks through its sections and says what each one covers. ### Why FDA wrote it Two nominators, Wells Pharmacy Network and LDT Health Solutions, had proposed BPC-157-related substances for FDA's 503A bulks list, and both nominations were withdrawn. FDA evaluated BPC-157 (free base) and BPC-157 acetate "on its own initiative" and looked at one use, ulcerative colitis. The nominations also named Crohn's disease, celiac disease and tendonitis, and FDA did not evaluate those because the nominations lacked enough information. Source: [FDA briefing document, introduction](https://www.fda.gov/media/193343/download?ref=curo.ghost.io). ### Section II.A: is the substance well characterized? This section starts with names. FDA says BPC-157 is a common name and not a United States Adopted Name, and that different salts and derivatives are sold under it. It then gives the free base and the acetate salt separate identifiers. It also records a mismatch in the nomination packages: certificates for the acetate that carried the free base's CAS number, formula and molecular weight. ### Section II.B: has it been used in compounding? FDA reports that outsourcing facility product data from January 2017 to June 2025 listed no compounded drug products containing BPC-157 (free base) or BPC-157 acetate. It also writes that the available literature "is too limited for FDA to understand the historical use" in compounded drug products. The section notes that WADA lists BPC-157 under S0, Non-approved substances. ### Section II.C: is there evidence of effectiveness? FDA found one randomized, double-blind, placebo-controlled study in ulcerative colitis, reported only as a 2005 meeting abstract. FDA wrote that "Based on the available data, there is a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating UC." It also noted that current guidelines for managing ulcerative colitis do not mention BPC-157. ### Section II.D: what is known about safety? The nonclinical part reviews rat studies of stomach, liver and fistula injury, and rat and dog toxicity studies that FDA read as showing some safety signals. The human part counts five clinical studies, all small and short, and three adverse event reports where FDA could not tell whether BPC-157 was the cause. FDA's summary: "There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate." ### Section III: the conclusion FDA balanced characterization, historical use, effectiveness and safety and wrote: "Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List." The document evaluates one use and one list. It does not say whether any other use of BPC-157 is lawful. ### Where to read more The [BPC-157 FDA status page](https://sites.google.com/view/bpc-157-research/is-bpc-157-fda-approved?ref=curo.ghost.io) quotes the FDA and WADA records with their dates, and the [BPC-157 research page](https://sites.google.com/view/bpc-157-research/bpc-157-research?ref=curo.ghost.io) lists the studies by model. For research material, [Curo's recovery catalog](https://curo.you/u/google-sites?to=%2Fproduct-catalog%2Frecovery-regenerative-research&utm%5Fsource=ghost&utm%5Fmedium=referral&utm%5Fcampaign=bpc%5F157&utm%5Fcontent=ghost%5Fcatalog) lists a BPC-157 5mg vial, [Curo's lot certificate library](https://curo.you/u/google-sites?to=%2Fcoa&utm%5Fsource=ghost&utm%5Fmedium=referral&utm%5Fcampaign=bpc%5F157&utm%5Fcontent=ghost%5Fcoa) lists reports by lot number and [Curo's testing standard page](https://curo.you/u/google-sites?to=%2Ftesting&utm%5Fsource=ghost&utm%5Fmedium=referral&utm%5Fcampaign=bpc%5F157&utm%5Fcontent=ghost%5Ftesting) defines the report fields. Sources checked October 15, 2026\. Reference information for laboratory research.